ModernaTX, Inc. is advancing its mRNA-1647 cytomegalovirus vaccine through a Phase 2 clinical trial, focusing on both CMV-seronegative and seropositive healthy adults aged 18-40. The successful development of this vaccine could address a significant unmet need in CMV prevention, particularly in congenital infections. The market potential is substantial, given the prevalence of CMV and the lack of approved vaccines. Competitive landscape includes other vaccine candidates in development, but Moderna's established mRNA technology platform provides a competitive edge. Diligence should focus on safety data and immunogenicity results, as these will be critical for advancing to Phase 3 trials and eventual commercialization.